‘Every dollar is mobile’: California’s rich snap up New Zealand ‘golden visas’

Image
Applications for indefinite right to work, live and study in the country have risen after rules were eased 🔥 EXCLUSIVE PARTNER OFFER AJAZZ AJ179 PRO PAW3395 Lightweight Wired Wireless Mouse with Magnetic Charging Base Ergonomic Macro Gaming Mouse for PC Laptop Special Price ⚡ Flash sale! Get the best deals on AliExpress today. Hurry, stocks are limited! 🛒 Buy Now on AliExpress → Affiliate link — Commission earned at no extra cost to you 📰 Original source: https://www.ft.com/content/1cf8821e-7ffa-4620-89f9-f56c11a6298e?syn-25a6b1a6=1 © EcoNews DZ — Global Economic & Financial News

Haya Therapeutics Signs $1 Billion Deal with Eli Lilly




Haya Therapeutics, a Swiss biotech founded in 2019 by Algerian biologist Samir Ounzain, has signed a $1 billion deal with Eli Lilly. Based in Lausanne, the company develops RNA-based therapies to treat severe diseases by exploring the "dark genome."

The agreement focuses on identifying drug targets for obesity and associated metabolic diseases. The contract includes several milestone payments, from preclinical to commercial stages, providing a major boost to the start-up’s growth.

About Samir Ounzain:

Samir Ounzain was born in 1983 in Koléa, Algeria. After growing up in the UK, he moved to Switzerland, where he founded Haya Therapeutics after working at the Lausanne University Hospital (CHUV). He holds a degree in biochemistry and molecular biology from the University of Leeds and a PhD in molecular cardiology from the University of Leicester.




Comments

Popular posts from this blog

Writing a Thesis or Paper with AI Tools

Xi wants China to boost demand. Why isn’t it working?

7 Best AI Applications to Enhance Scientific Research